Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinﬂammatory potential are enriched in the adult human liver by Harmon, Cathal et al.




Frontline  Research Article
Tissue-resident Eomeshi T-betlo CD56bright NK cells
with reduced proinflammatory potential are enriched in
the adult human liver
Cathal Harmon1, Mark W. Robinson1, Ronan Fahey1, Sarah Whelan1,
Diarmaid D. Houlihan2, Justin Geoghegan2 and Cliona O’Farrelly1,3
1 School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity
College Dublin, Dublin, Ireland
2 Liver Unit, St. Vincent’s University Hospital, Dublin, Ireland
3 School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin,
Ireland
The adult human liver is enriched with natural killer (NK) cells, accounting for 30–50% of
hepatic lymphocytes, which include tissue-resident hepatic NK-cell subpopulations, dis-
tinct from peripheral blood NK cells. In murine liver, a subset of liver-resident hepatic NK
cells have altered expression of the two highly related T-box transcription factors, T-bet
and eomesodermin (Eomes). Here, we investigate the heterogeneity of T-bet and Eomes
expression in NK cells from healthy adult human liver with a view to identifying human
liver-resident populations. Hepatic NK cells were isolated from donor liver perfusates and
biopsies obtained during orthotopic liver transplantation (N = 28). Hepatic CD56bright NK
cells were Eomeshi T-betlo, a phenotype virtually absent from peripheral blood. These
NK cells express the chemokine receptor CXCR6 (chemokine (C-X-C motif) receptor 6), a
marker of tissue residency, which is absent from hepatic CD56dim and blood NK cells.
Compared to blood populations, these hepatic CD56bright NK cells have increased expres-
sion of activatory receptors (NKp44, NKp46, and NKG2D). They show reduced ability to
produce IFN-γ but enhanced degranulation in response to challenge with target cells.
This functionally distinct population of hepatic NK cells constitutes 20–30% of the total
hepatic lymphocyte repertoire and represents a tissue-resident immune cell population
adapted to the tolerogenic liver microenvironment.
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Introduction
Natural killer (NK) cells are group 1 innate lymphoid cells,
important in antiviral and tumor immunity. In human peripheral
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blood (PB), two subsets of NK cells are readily distinguished by
their expression of CD56, a cell surface glycoprotein. CD56bright
NK cells are potent producers of immunoregulatory cytokines,
such as interferon (IFN) γ and tumor necrosis factor (TNF) α,
and are commonly attributed as the precursor population of the
more mature CD56dim NK cells [1, 2]. Upon maturation, CD56dim
NK cells gain potent cytotoxic effector functions, and produce
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less cytokines than the CD56bright population [1, 2]. Studies in
knockout mice have identified a number of transcription factors
essential for the developmental program of NK cells, such as Nfil3,
Ets-1, Id2, Id3 [3–5], as well as the two highly related T-box tran-
scription factors, T-bet and eomesodermin (Eomes) [6, 7]. In the
bone marrow (BM), T-bet expression is initially repressed, allow-
ing the development of Eomes+ NK-cell precursors, with T-bet
expression subsequently increased during the final stages of NK-
cell maturation [6].
While conventional NK cells circulate in the PB, transiting
through several organs, significant NK-cell populations also per-
manently reside in tissues such as the lung, gut, uterus, and
liver and may develop there [8]. Among these tissue-resident
NK-cell populations, the role of uterine NK cells in successful
pregnancy is well described [9]; however, the functions of other
heterogeneous tissue-resident NK-cell populations remain largely
unknown. Within these tissue microenvironments, it is evident
that the developmental, functional, and phenotypic features of
NK-cell subsets are poorly characterized compared to their PB
counterparts [10].
The adult human liver contains a unique and extensive lym-
phoid repertoire. There is a predominance of innate lymphoid cells
including NK cells, NKT cells, mucosal-associated invariant T cells
and γδ T cells in the liver, in addition to the presence of con-
ventional CD4+ and CD8+ lymphocytes of the adaptive immune
system [11–13]. Over 40% of the hepatic lymphoid population are
NK cells, making the liver the most “NK-populated” organ in the
body. These human liver NK cells are enriched in CD56bright cells
and display a range of cell-surface markers associated with tissue
residency including CD103, CD69, and CD49a [13–15]. Hepatic
NK cells play important roles in viral and tumor surveillance, as
well as tissue homeostasis and immune regulation [16–19]. How-
ever, these divergent functions have yet to be attributed to distinct
NK cell subsets and it is not clear whether circulating and tissue-
resident NK cells are involved in distinct or overlapping immuno-
logical roles within the liver.
Murine liver resident NK cells (CD49a+ DX5−) have been
shown to differentiate independently of Eomes, in contrast to con-
ventional NK cells [7]. These T-bet+ Eomes− liver-resident NK
cells express a broad range of cytokines and chemokines (inter-
leukin (IL) 2, IL-4, GM-CSF, TNF, CCL3, and IFN-γ) and contribute
to the immune response against intracellular pathogens such as
Francisella tularensis [7]. Expression of the chemokine receptor
chemokine (C-X-C motif) receptor 6 (CXCR6) by CD49a+ DX5−
NK cells is believed to be important for homing to and retention
in the liver [20]. A comparable Eomes− CD49a+ population of
CD56bright NK cells is present at low frequencies in human liver
and highly express T-bet, in contrast to conventional NK cells that
are Eomes+ T-bet+ [14]. The human Eomes− CD49a+ CD56bright
NK-cell population was only identified in 12 of 29 livers examined,
making up 0.11–12.7% (average 2.3%) of the total CD3−CD56+
lymphocyte population [14]. Despite this low frequency of detec-
tion of Eomes− CD49a+ NK cells in humans, almost all human
hepatic CD56bright NK cells express the chemokine receptor CXCR6
and the tissue-residency marker CD69, enabling them to traf-
fic to hepatic sinusoidal spaces [15]. This indicates that other
tissue-resident hepatic NK-cell populations, distinct from the pre-
viously described Eomes− CD49a+ CD56bright NK cells, exist in
humans.
In the present study, we aimed to define the expression of
Eomes and T-bet within healthy adult human liver NK-cell pop-
ulations, with the goal of validating the tissue-resident status of
human hepatic CD56bright NK cells. Using LP and biopsies taken
from healthy organs during liver transplant, we identified a unique
Eomeshi T-betlo population of CD56bright NK cells in adult human
liver. These Eomeshi T-betlo CD56bright NK cells are phenotypically
distinct from PB NK-cell populations, display increased cytotoxic
function, and reduced pro-inflammatory cytokine production. We
propose that this functionally distinct population of hepatic NK
cells is of importance in the context of tissue homeostasis, liver
infection, malignancy, and transplantation.
Results
Human hepatic CD56bright NK cells are characterized
by increased Eomes and reduced T-bet expression
NK cells account for 51.4 ± 3% (n = 28) of LP lymphocytes com-
pared to 36.5± 5.8% of lymphocytes from liver biopsies (p= 0.06,
n = 5; using the flow cytometry gating detailed in Fig. 1A). In
contrast, NK cells account for only 17.3 ± 2.3% of peripheral lym-
phocytes in matched blood (Fig. 1B, n = 28). CD56bright NK cells
were enriched in LP (43.8 ± 2.7%) and biopsy (53.3 ± 7.9%);
while significantly fewer CD56bright NK cells were detected in PB
(9.4 ± 1.1%) (Fig. 1C). The ratio of CD56dim CD16+ to CD56bright
CD16+/− NK cells in the perfusate showed high levels of interindi-
vidual variation, ranging from 0.3:1 to 4:1, and was distinct from
PB where the ratio was usually greater than 10:1. The variation in
CD56dimCD16+ to CD56bright CD16+/− hepatic NK-cell ratios was
not attributable to the age or sex of the organ donor (data not
shown).
A novel population of Eomes− NK cells have been described
in murine liver and more recently in human liver in both healthy
and malignant tissue [14]. In the present study this Eomes− NK-
cell population was not detectable in human LP, donor biopsy or
PB, although a unique population of Eomeshi T-betlo NK cells was
identified in liver (Fig. 2A). This population accounts for nearly
50% of perfusate NK cells (47.2 ± 3.4%), and 61.7 ± 2.8% of
biopsy NK cells (Fig. 2B). Less than 2% of peripheral NK cells
express this phenotype (1.8 ± 0.6%) (Fig. 2B). This phenotype is
almost exclusively confined to the CD56bright subset. In LP 89.5 ±
1.8% of CD56bright cells are Eomeshi T-betlo, while only 7.5 ±
1.5% of perfusate CD56dim NK cells possesses this phenotype
(Fig. 2E and F). Similarly, 87.5 ± 4% of biopsy CD56bright NK
cells were Eomeshi Tbetlo, with only 2.8 ± 1% of CD56dim NK cells
sharing this phenotype. Small proportions of blood CD56bright and
CD56dim NK cells were also Eomeshi T-betlo (10.4 ± 2.3% and
1.8 ± 0.5%, respectively). This altered T-bet and Eomes usage
is corroborated by quantification of EOMES and TBX21 mRNA
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Figure 1. NK cells, in particular CD56bright NK
cells, are enriched in LP compared to matched
PB. (A) Representative gating strategy for NK
cells from LP, matched PB, and donor LB.
NK cells were identified from viable CD45+
lymphocytes as CD56+CD3−. NK-cell subsets
were identified as CD56bright CD16−/+ and
CD56dim CD16+. (B) Total NK cells in LP (ᴏ), DB
() PB () as a percentage of CD45+ lympho-
cytes. (C) CD56bright CD16−/+NK-cell frequen-
cies in LP (ᴏ), LB () and PB () as a percentage
of total NK cells. n = 28 LP, n = 5 LB, n = 28
PB samples. (A-C) Data are shown as mean
± SEM and are representative of 28 indepen-
dent experiments. **p < 0.01, ***p < 0.001. Data
were analyzed using Kruskal–Wallis test, with
Dunn’s multiple comparison test.
levels in LP and PB NK cell populations. EOMES expression is
significantly increased in perfusate NK cells compared to blood
cells (p = 0.002), while TBX21 expression was not significantly
different (p = 0.093) (Fig. 2I). As the NK cell subsets isolated
from LP and liver biopsy (LB) samples shared similar phenotypes,
LP-derived NK cells were used in all subsequent experiments.
CXCR6 has previously been identified as a marker of tissue resi-
dent NK cells in themurine liver. Themajority of hepatic CD56bright
NK cells express CXCR6 (68.3± 8.2%, Fig. 2J, n= 8), in contrast to
the PB (3.1 ± 2%). This phenotype is not reflected in the CD56dim
population that do not express CXCR6 in the liver (1.33 ± 0.28%)
or PB (0.6 ± 0.25%, Fig. 2K). This suggests that these hepatic
CD56bright NK cells may represent a human-specific tissue resident
population.
Hepatic CD56bright NK cells display increased
expression of NCRs and NKG2D
We next analyzed NK-cell receptors to determine if hepatic
CD56bright NK cells display a unique profile of activatory recep-
tors (Fig. 3). NKG2D, a C-type lectin binding receptor that rec-
ognizes stress-induced ligands such as MHC class I polypeptide
associated sequence A (MIC-A), MIC-B, and ULBPs, is expressed
on the majority of both hepatic and PB NK cells, but is signifi-
cantly increased in hepatic NK cells with the highest expression in
the CD56bright subset (97.5 ± 0.9% vs. 92.6 ± 1.7%, p = 0.001,
Fig. 3B). The expression of the activatory receptor NKG2C that
recognizes human leukocyte antigen E molecules, was signifi-
cantly lower in CD56bright hepatic NK cells compared to their blood
counterparts (8.6 ± 2.3% vs.19.1 ± 6.1%, p = 0.0017, Fig. 3C).
Expression of the related inhibitory receptor natural-killer group 2,
member A (NKG2A), was higher in CD56bright hepatic NK cells
compared to matched PB NK cells (13.2 ± 10.5% vs. 5.1 ± 3.8%
p = 0.02, Fig. 3D).
Hepatic NK cells also have distinct expression of the natural
cytotoxicity receptors NKp46 and NKp44. NKp46 is expressed on
the majority of both peripheral and hepatic NK cells, although
slightly more hepatic CD56bright NK cells express this receptor
(93.1 ± 3.7%) than peripheral cells (87.7 ± 2.3%, p = 0.006,
Fig. 3E). Furthermore, the receptor is expressed at a higher con-
centration per cell on these cells (MFI 1271 ± 400) compared
to peripheral CD56bright NK cells (MFI 884 ± 513, p = 0.03).
No differences were seen between natural cytotoxicity receptor
expression on hepatic and peripheral CD56dim NK cells. NKp44 is
an activatory receptor that is not expressed on resting NK cells. Not
surprisingly, NKp44 is low or absent on PBNK cells but theNKp44+
population is significantly increased in the hepatic CD56bright NK
cell population (8.9 ± 3.3%, p = 0.002, Fig. 3F) confirming the
previously described activated phenotype of hepatic NK cells [13].
Hepatic NK cell populations have less granzyme B but
more perforin than peripheral NK populations
To assess whether the cytotoxic potential of hepatic NK cells
is altered we performed intracellular staining for granzyme B
and perforin. Only 60% of hepatic CD56bright NK cells express
granzyme B compared to over 75% in the blood (Fig. 3H), with
significantly lower expression of the molecule per cell (MFI 678
± 306) compared to blood CD56bright cells (MFI 2021 ± 1258,
P = 0.03, Fig. 3I). In contrast, a significantly higher proportion of
hepatic CD56bright NK cells express perforin (92 ± 11%) com-
pared to blood CD56bright NK cells (83.7 ± 11.7%, P = 0.02,
Fig. 3K). No significant difference was seen in the amount of
C© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
2114 Cathal Harmon et al. Eur. J. Immunol. 2016. 46: 2111–2120
Figure 2. Hepatic CD56bright NK cells have unique transcription factor usage and express markers of tissue residency. (A) Representative FACS
plots of Eomes and T-bet expression in LP, matched PB, and donor LB. (B) Percentage of Eomeshi T-betlo cells in the total NK-cell population from
LP, LB and PB. (C) Percentage of Eomeslo T-bethi cells in the total NK-cell population from LP, LB, and PB. (D) Representative FACS plots of Eomes
and T-bet expression in CD56bright and CD56dim subsets from LP, PB, and DB. (E, F) Percentage of Eomeshi T-betlo cells in the CD56bright (E) and
CD56dim (F) NK-cell populations from LP (n = 18), LB (n = 5), and PB (n = 18). (G, H) Percentage of Eomeslo T-bethi cells in the CD56bright (G) and
CD56dim (H) NK-cell populations from LP (n = 18), LB (n = 5) and PB (n = 18). (I) Relative mRNA expression of TBX21 and EOMES, using RPS15
as a reference gene, in NK cells isolated from non-matched PB (n = 6) and LP (n = 6). (J) Representative histograms of CXCR6 expression in LP
(solid line), LB (dashed line), and PB (dotted line) in NK-cell subsets, with FMO control (grey tint). (K, M) Percentage of CXCR6+ CD56bright (K) and
CD56dim (M) NK-cell subsets in LP (n = 8), LB (n = 5), PB (n = 8). (A–M) Data are shown as mean ± SEM and are representative of 18 independent
experiments.*p < 0.05; **p < 0.01; ***p < 0.001.All data were analyzed using Kruskal–Wallis test, Dunn’s multiple comparison test, except for the
mRNA expression (I), which was analyzed by Mann–Whitney U test.
perforin expressed per cell (LP MFI 2067 ± 787, PB MFI 2794
± 1108, p = 0.21, Fig. 3L).
Hepatic NK cells demonstrate increased cytotoxicity
compared to PB NK cells
To examine cytotoxic function, hepatic and PBNK cells, isolated by
negative selection from donor perfusate and healthy donor blood,
were incubated with MHC class I deficient K562 target cells in the
presence or absence of IL-2. Hepatic NK cells display significantly
higher CD107a expression compared to PB NK cells from healthy
donors, with significant differences between CD56bright subsets
(Fig. 4). In the absence of cytokine stimulation hepatic CD56bright
NK cells display enhanced CD107a expression compared to PB
(28.6 ± 2.5% vs. 9.3 ± 1.3%, p = 0.011, Fig. 4B). No signif-
icant difference was seen between hepatic and PB CD56dim NK
cells (13.5 ± 2.7% versus 11.9 ± 1.5%, p = 0.8, Fig. 4B). With
the addition of IL-2, expression of CD107a increased in hepatic
CD56bright NK cells (53.2 ± 8.6%) and hepatic CD56dim cells (38.8
± 10.4%). No difference is seen between the proportions of IFN-
γ+ cells between CD56bright (21.4 ± 18.3%) and CD56dim (24.1
± 14.9%) within the liver after stimulation with IL-2 and tar-
get cells. This differs markedly to PB where more CD56bright cells
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Figure 3. Expression of cytotoxic molecules and receptors in LP and PB CD56bright NK cells. (A) Representative histograms of NKG2D, NKG2C,
NKG2A, NKp46, and NKp44 expression in LP (solid line) and matched PB (dotted line) CD56bright NK cells with FMO control (gray tint). Percentage
of CD56bright NK cells positive for NKG2D (B), NKG2C (C), NKG2A (D), NKp46 (E), NKp44 (F), in LP (n = 17) and PB (n = 17). (A–F) Data are presented
as mean ± SEM, and are representative of 17 independent experiments (G) Representative histograms of granzyme B and perforin expression
in LP (solid line) and PB (dotted line) CD56bright NK cells, with FMO control (gray tint). (H) Percentage positive and (I) MFI values of granzyme B
expression in LP (n = 6) and PB (n = 6) CD56bright NK cells. (J) Representative histograms of perforin expression in LP (solid line) and PB (dotted
line) CD56bright NK cells, with FMO control (gray tint). (K) Percentage positive and (L) MFI values of granzyme B expression in LP (n = 6) and PB
(n = 6) CD56bright NK cells. (G–L) Data are presented as mean ± SEM and are representative of six independent experiments (B–F, H–L). *p < 0.05;
**p < 0.01; Wilcoxon signed-rank test.
express IFN-γ compared to CD56dim cells (68.6 ± 7.4% versus
32.3 ± 6.4%, p = 0.001, Fig. 4D and E). This difference is due
to a reduced ability to produce IFN-γ specifically in the hepatic
CD56bright NK cell population. Hepatic CD56bright NK cells also
produce significantly less IFN-γ in response to IL-2 stimulation
alone, compared to their PB counterparts (3.2 ± 1.6% versus 21.4
± 7.5%, p = 0.01, Fig. 4D). IFN-γ production by hepatic and PB
CD56dim cells is largely comparable.
Due to enhanced degranulation of the hepatic CD56bright NK-
cell population and the fact that the hepatic CD56bright NK cell pop-
ulation is enriched for the Eomeshi T-betlo phenotype, we exam-
ined the response of Eomeshi T-betlo and Eomeslo T-bethi subsets
to target cell and cytokine stimulation. Hepatic NK cells were incu-
bated with target cells, K562 cells, in the presence or absence of
IL-2. CD56bright NK cells were divided into two groups: CD56bright
Eomeshi T-betlo, and CD56bright Eomeslo T-bethi. No difference was
seen in CD107a expression between CD56bright subsets either in
the absence (26.7 ± 3% versus 22.4 ± 2.6%, p = 0.08, Fig. 4G)
or presence of cytokine stimulation (53.7 ± 4.7% versus 50.6 ±
4.3%, p = 0.8, Fig. 4G). However, a significantly lower proportion
of CD56bright Eomeshi T-betlo NK cells express IFN-γ with cytokine
and target cell stimulation (15.2 ± 5.4% versus 27.8 ± 3.8%,
p = 0.01, Fig. 4H).
Liver-conditioned media suppresses IFN-γ production
by PB NK cells
Liver-conditioned media (LCM) is a rich source of liver-derived
cytokines, growth factors, and chemokines (unpublished data). In
order to investigate the effect of the hepatic microenvironment on
NK-cell function, PB NK cells were isolated from healthy donors
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Figure 4. Comparison of degranulation and IFN-g production between LP and PB NK cells. (A) Representative FACS plots of CD107a and IFN-g
staining in response to IL-2 and K562 target cell stimulation. (B–E) Percentage of CD56bright and CD56dim NK-cell subsets positive for CD107a
(B, C) and IFN-g (D, E) in LP (black bars) and PB (white bars) in response to IL-2 and/or K562 target cell stimulation (LP, n = 7; PB, n = 5). (A–E)
Data are presented as mean ± SEM and are representative of eight independent experiments. *p < 0.05; Mann–Whitney U test. (F) Representative
FACS plots of CD107a and IFN-g staining in hepatic Eomeslo T-bethi and Eomeshi T-betlo CD56bright NK cells stimulated with IL-2 and/or K562
target cells. (G, H) Percentage of hepatic Eomeslo T-bethi (black bars) and Eomeshi T-betlo (white bars) NK cells positive for CD107a (G) and IFN-g
(H) (n = 5). (F–H) Data are presented as mean ± SEM and are representative of five independent experiments. *p < 0.05; Wilcoxon signed-rank test.
and treated with LCM for 24 h. NK cells were subsequently stim-
ulated with IL-2 and K562 target cells as described above. No
significant difference was observed in the expression of CD107a
in either CD56bright (43.3 ± 6.1% vs. 34.9 ± 9.9%, p = 0.62,
Fig. 5B) or CD56dim (36.0 ± 10.5% vs. 23.4 ± 7.4%, p = 0.25,
Fig. 5D) NK-cell populations after treatment with LCM. Interest-
ingly, production of IFN-γ was significantly reduced in CD56bright
(47.6 ± 0.9% vs. 10.9 ± 4.9%, p = 0.01, Fig. 5C) and CD56dim
NK cells (25.7 ± 1% vs. 4.7 ± 1.4%, p = 0.005, Fig. 5E) suggest-
ing that the liver microenvironment can directly suppress NK-cell
proinflammatory cytokine production.
Discussion
In this study, we characterized the diverse NK repertoire of healthy
human liver and have identified a novel subpopulation of hepatic
NK cells with unique phenotypic features, effector function, and
transcriptional regulation, similar to those recently described by
Stegmann et al. [21]. As previously described, we have shown that
the liver is enriched with NK cells, accounting for more than half
of hepatic lymphocytes, with the CD56bright subset making up over
40% of these. The Eomeshi Tbetlo CXCR6+ hepatic NK-cell popula-
tion we identify represents a novel human tissue resident popula-
tion. While murine models of NK-cell differentiation have proven
invaluable in furthering our understanding of NK-cell biology, sig-
nificant differences in the structure and immune repertoire of the
liver exist between man and mouse. As such, data from murine
liver may not provide a full view of the heterogeneity of human
hepatic NK cells and the spectrum of tissue resident immune cells.
Eomeshi Tbetlo hepatic NK cells have increased expression of acti-
vating receptors, such as NKG2D, NKp44, and NKp46, which rec-
ognize stress-induced ligands and viral and tumor-associated anti-
gens. In addition, these NK cells show increased expression of the
cytotoxic molecule perforin. While we have found that granzyme
B expression is reduced in hepatic NK cells, it has previously
been demonstrated that these cells show increased expression of
granzymes A and K [13]. In line with this activated phenotype and
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Figure 5. The LCM suppresses IFN-g production by PB NK cells. (A–E) LCM was produced by culturing portions of donor LB for 72 h in X-VIVO 15
media. Supernatants (5% v/v) from this culture were used to treat PB NK cells for 24 h. NK cells were then stimulated with IL-2 and K562 target
cells. (A) Representative FACS plots of CD56bright and CD56dim NK cells treated with 5% LCM or untreated. (B, C) Percentage of CD56bright NK
cells positive for CD107a (B) and IFN-g (C) in response to IL-2 and K562 target cell stimulation with/without 5% LCM. (D, E) Percentage of CD56dim
NK cells positive for CD107a (D) and IFN-g (E) in response to IL-2 and K562 target cell stimulation with/without 5% LCM. (A–E) Data are presented
as mean ± SEM and are representative of three independent experiments. *p < 0.05; **p < 0.01; Mann–Whitney U Test.
increased cytotoxic molecule expression, hepatic NK cells display
increased degranulation in response to target cell stimulation. In
PB, the CD56bright subset is normally considered poorly cytotoxic
and produces large amounts of proinflammatory cytokines. In con-
trast, hepatic CD56bright NK cells display enhanced degranulation
and significantly reduced IFN-γ production, with no difference
seen in the expression of IFN-γ between CD56bright and CD56dim
hepatic NK cells. This difference between PB and hepatic popula-
tions can be attributed to the presence of the Eomeshi Tbetlo cells
in the hepatic CD56bright NK-cell population, which produce sig-
nificantly less IFN-γ compared to conventional Eomeslo Tbethi PB
NK cells. This functional phenotype appears to be driven, as least
in part, by the liver microenvironment, as treatment of PB NK cells
with LCM leads to a significant reduction of IFN-γ positive NK cells
following cytokine and target cell stimulation.
The origin of hepatic Eomeshi T-betlo NK cells remains to be
established. We have hypothesized that some hepatic NK-cell pop-
ulations differentiate locally from lymphoid progenitors in the
adult human liver [22, 23]. Healthy liver tissue contains a com-
plex cytokine milieu and we have identified cytokines essential of
progenitor differentiation and NK-cell activation including IL-7,
IL-15, IL-12, IL-18, and IL-2 within healthy liver tissue [24–26].
As evidenced in the present study, the local microenvironment is
also capable of inducing liver specific phenotypical and functional
changes in BM-derived NK cells which traffic to the liver. The liver
is a naturally tolerogenic environment, which maintains unique
anti-inflammatory status even in the presence of immune activat-
ing dietary antigens and bacterial components. In this context,
Eomeshi T-betlo NK cells may provide a potent cytotoxic cellu-
lar response while minimizing wider tissue inflammation through
reduced pro-inflammatory cytokine production, helping to main-
tain the overall tolerogenic environment in the liver.
The high interindividual variation in the relative proportions
of hepatic NK-cell populations observed in this study may be of
clinical significance during malignancy, viral infection, autoim-
munity, and transplantation tolerance and explain inter individ-
ual variation in pathological severity of these conditions [27, 28].
The significance of NK-cell subset heterogeneity is driven by the
differing immunological roles of NK-cell subpopulations. While
conventional NK cells are thought of as predominantly cytotoxic
and proinflammatory, emerging data suggest that NK cells can
also play immunoregulatory roles in the liver, helping to maintain
tissue homeostasis [16, 19, 29], and minimize immune activation
during viral infection [17, 30]. Highlighting their immunoregula-
tory potential, hepatic Eomeshi Tbetlo CD56bright NK cells express
TRAIL, enabling these cells to regulate both virally-infected hep-
atocytes and activated cytotoxic T cells [21]. High levels of
interindividual NK-cell subset heterogeneity may also help explain
the conflicting reports on the influence of NK-cell accumulation
on clinical outcomes in hepatocellular carcinoma and colorec-
tal liver metastasis. Accumulation of NK cells has been linked
with increased survival in hepatocellular carcinoma [31, 32] and
significantly worse survival rates in hepatic colorectal cancer
metastasis [33, 34]. The ability of hepatic NK cells to both regulate
and drive liver pathology highlights the importance of defining the
complexity and heterogeneity of tissue-resident immune cell popu-
lations and in particular, this abundant hepatic CD56bright Eomeshi
Tbetlo NK-cell population in the context of human liver disease.
Materials and methods
Collection of LP during orthotopic liver transplantation
Samples were collected from donor livers (n = 28) during ortho-
topic liver transplantation at St. Vincent’s University Hospital.
During retrieval, the donor aorta and superior mesenteric vein
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were flushed with University of Wisconsin (UW) solution (Bristol-
Myers Squibb, Uxbridge, UK) at the time of exsanguination. The
liver was flushed again with UW solution after excision of the
organ until all blood was removed and the perfusate appeared
clear, at which time the liver was placed in a container with UW
solution and packed on ice for transportation. Donor livers were
transplanted within 12 hours. At implantation, after completion
of the upper inferior vena cava anastomosis, livers were flushed
with normal saline through the portal vein to wash out the UW
before reperfusion. This wash-out fluid was collected from the
inferior vena cava; the UW transportation solution was also col-
lected. A matched donor blood sample was taken at the time of
organ retrieval. Peripheral blood was obtained from anonymized
blood donors from the Irish Blood transfusion Board (IBTS). All
protocols were approved by St. Vincent’s University Hospital Ethics
Committee in accordance with the ethical guidelines of the 1975
Declaration of Helsinki.
Isolation of hepatic mononuclear cells from LP, LB,
and PB
Hepatic mononuclear cells (HMNCs) were isolated from donor
LPs, as previously described [35], by filtration through 70 μm
filters (BD Biosciences, Erembodegem, Belgium) followed by cen-
trifugation at 1200 rpm for 10 min. The supernatant was aspirated
and the cells resuspended in RPMI 1640 medium, supplemented
with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin
(Gibco, Wicklow, Ireland). HMNCs were separated from this sus-
pension by density gradient centrifugation using Ficoll-PaqueTM
PLUS (GE Healthcare, Uppsala, Sweden) and residual red blood
cells were removed by adding red cell lysis solution (Sigma-
Aldrich, Wicklow, Ireland). HMNCs were isolated from donor liver
biopsies taken at the time of transplantation by mechanical and
enzymatic digestion, as previously described [12]. Matched PB
mononuclear cells (PBMCs) were also isolated by density cen-
trifugation.
Preparation of LCM
Wedge biopsies taken at the time of transplantation were used
to generate tissue conditioned media. Tissue samples were mea-
sured and weighed. Tissue was then cut into sections measuring
approximately 0.5 × 0.5 × 0.5cm. These were placed in a 24-well
culture plate and 350 μL of X-VIVO (Lonza Biologics, Slough, UK)
media was added to each well and incubated for 72 h at 37°C.
Following incubation the supernatant was centrifuged to remove
cell debris and stored at −20°C until use.
Phenotypic analysis of NK cells
HMNCs or PBMCs, isolated from donor perfusate or blood,
were stained with fluorescently labelled monoclonal antibodies to
determine the phenotypic differences between hepatic and periph-
eral NK cells. The following antibodies were used: CD45 (HI30)
BV510, CD3 (UCHT1) BV421, CD56 (NCAM16.2) BV650, CD16
(3G8) PE-Cy7, CD16 (3G8) BV605, NKp46 (9E2) PE-Cy7 (BD Bio-
sciences, Franklin Lakes, NJ, USA), NKp44 (P44-8) APC, NKG2D
(1D11) PE (Biolegend, San Diego, CA, USA), NKG2A (# 131411)
APC, NKG2C (# 134591) AF488 (R&D Systems Minneapolis, CA,
USA). Intracellular staining was performed using FoxP3 stain-
ing buffer (00-5523-00, eBiosciences, San Diego, CA, USA) and
the following antibodies were used: Perforin (δG9) PE-CF594,
Granzyme B (GB11) AF700 (BD Biosciences), Eomes (WD1928)
AF488 and T-bet (ebio4B10) PE (Biolegend). Dead cell exclusion
was carried out using fixable viability stain 780 (BD Biosciences).
CD107a (H4A3) APC-H7 and IFN-γ (B27) PE-Cy7 were used for
functional experiments. Flow cytometric analysis was carried out
using an LSR Fortessa (BD Biosciences) and data was analyzed
using FlowJo (Version 7.6.5, Tree Star, Ashland, OR, USA).
Quantitative PCR of Eomes and TBX21
Total RNA was extracted from CD3− CD56+ NK cells (iso-
lated as detailed below) from fresh LPs and PB from healthy
donors using TRIzol reagent (Thermo Fisher Scientific, Pais-
ley, UK). During RNA extraction glycogen (Sigma-Aldrich) was
added as an RNA carrier and reverse transcription was per-
formed using the SuperScript VILO Master Mix (Thermo Fisher
Scientific). Quantitative PCR was performed using the fol-
lowing primers: RPS15 forward 5′-CGGACCAAAGCGATCTCTTC;
RPS15 reverse 5′-CGCACTGTACAGCTGCATCA; EOMES forward
5′-CCGACAATAACATGCAGGGC; EOMES reverse 5′-TGCAGTCG
GGGTTGGTATTT; TBX21 forward 5′-AACCACCTGTTGTGGTC
CAA; and TBX21 reverse 5′-ATGGGAACATCCGCCGTCC. Quan-
titative PCR was run using the PowerUp SYBR Green Master Mix
(Thermo Fisher Scientific) on a StepOnePlus Real-Time PCR Sys-
tem (Thermo Fisher Scientific). RPS15 was used as a reference
gene to generate normalized relative expression values for TBX21
and EOMES.
Isolation of NK cells from LP and PB
CD3−CD56+ NK cells were isolated from fresh LPs and PB from
healthy donors by negative selection using the NK-cell isolation kit
(130–092–657; Miltenyi Biotech, Teterow, Germany), as per the
manufacturers protocol. Briefly, mononuclear cells were labeled
with a biotin-conjugated antibody cocktail against lineage specific
targets. Anti-biotin microbeads were then added and the NK cells
were separated using a magnetic cell sorting (MACS) LS column.
Cells were then cultured in RPMI 1640 supplemented with 10%
FCS and 1% penicillin/streptomycin. After separation NK-cell pop-
ulations all had purities >90%, with an average purity of 96.9%
(LP) and 95.8% (PB).
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Cytoxicity assay
Degranulation of NK cells was measured by quantifying the
increase of cell-surface CD107a in response to co-incubation
with K562s, a MHC-deficient monocytic cell line. Briefly, freshly
isolated hepatic or PB NK cells were incubated overnight at
37°C in RPMI 1640 supplemented with 10% FCS and 1% peni-
cillin/streptomycin. K562s were cultured overnight under the
same conditions. K562s were then coincubated with NK cells at
an effector:target ratio of 5:1. Anti-human CD107a antibody was
added to each well to assess degranulation. Samples were then
incubated at 37°C for 4 h. After 1 h Golgistop (BD Biosciences)
was added to each sample. Following the 4 h incubation, samples
were washed with flow buffer and stained for CD56, CD3, CD45,
CD16, IFN-γ and the transcription factors Eomes and T-bet. Intra-
cellular staining was performed as above using the FoxP3 staining
buffer set (eBiosicence).***
Statistical analysis
Data are presented as mean ± standard error mean (SEM). Com-
parison of more than two groups was performed using Kruskal–
Wallis test, with Dunn’s multiple comparison test. For paired com-
parisons, Wilcoxon signed-rank test was used. For comparison of
two unmatched groups, Mann–Whitney U test was used. A p-value
of <0.05 was considered significant.
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